Pivotal trial met primary and all key secondary endpoints Dupixent significantly reduced itch at 12 weeks, and nearly three times as many Dupixent patients experienced reductions in both itch and skin ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application (sBLA) seeking approval for Dupixent for treating bullous pemphigoid (BP), a ...

April 21, 2025 – The FDA just approved the popular drug Dupixent for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular allergy meds ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 receptors to enhance T cell-mediated cancer cell attack.

Sanofi said its dupixent drug achieved significant improvements for the treatment of two skin diseases. The French pharmaceutical company said Wednesday that the drug met the primary and all key ...

Please provide your email address to receive an email when new articles are posted on . The updated label shows safety and efficacy in treating moderate to severe atopic dermatitis of the hands or ...

A woman holds a test tube in front of displayed Abbvie logo in this illustration (Reuters) - AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to ...

Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder. It’s the ...

Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...

April 25 (Reuters) - AbbVie (ABBV.N), opens new tab said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals ...